ProMIS Neurosciences, Inc. (PMN) AI Stock Analysis
PMN AI stock analysis summary
AI ResearchProMIS Neurosciences, Inc. (PMN) is a clinical-stage biotechnology company developing antibody therapies for neurodegenerative diseases like Alzheimer's and ALS. The company generated $7,558 in TTM revenue through June 30, 2026, while reporting an operating cash flow of -$22.9M in FY2022. Its balance sheet shows $53.5M in cash and short-term investments alongside a current ratio of 7.85 as of June 30, 2026.
- Market cap
- $73.1M
- Revenue (TTM)
- $7,558
- P/E
- —
- 1Y return
- -30.6% S&P 500 16.8%
- Avg. target
- $42.95 427.0% vs last close
Bull case
- Analysts maintain a positive outlook with 6 Strong Buy and 2 Buy recommendations alongside a mean price target of $42.95.
- The company holds liquid resources with $53.5M in cash and short-term investments and a current ratio of 7.85 as of June 30, 2026.
- Year-to-date share price performance is positive, posting a return of 19.3% through October 16, 2026.
Bear case
- The company generated minimal revenue of $7,558 over the trailing twelve months ended June 30, 2026.
- Long-term shareholders have faced heavy dilution, indicated by a 5-year share count change of 3760.8%.
- Shares delivered a 5-year return of -96.4%, trailing the S&P 500 return of 83.0%.
What ProMIS Neurosciences does
ProMIS Neurosciences, Inc. is a Canada-based precision medicine biotechnology company focused on neurodegenerative diseases such as Alzheimer's disease, amyotrophic lateral sclerosis, and multiple system atrophy. Founded in 2004 and rebranded in 2015, the company utilizes proprietary ProMIS and Collective Coordinates algorithms to identify disease-specific epitopes on misfolded proteins. Its pipeline features PMN310 targeting toxic oligomers in Alzheimer's, PMN267 addressing superoxide dismutase 1 and TAR-DNA binding protein 43 in ALS as well as alpha-synuclein in Parkinson's, and PMN442 targeting alpha-synuclein in multiple system atrophy.
Growth and profitability
Between FY2018 and FY2022, revenue fluctuated significantly, moving from $349 in FY2018 up to $16,680 in FY2021 before falling 51.2% to $8,139 in FY2022, representing a 5-year revenue CAGR of -3.8%. Net income was -$7.5M in FY2018 and -$18.06B in FY2022, impacted by an R&D expense of $16.09B and an operating margin of -287268384.4%. For the trailing twelve months ended June 30, 2026, revenue stood at $7,558, accompanied by an operating margin of 0.0%, an EPS of -$11.65, and a return on equity of -172.3%.
Balance sheet and cash flow
As of June 30, 2026, ProMIS Neurosciences held $53.5M in cash and short-term investments, with total assets of $56.7M and shareholders' equity of $49.4M. Its liquidity profile is supported by a current ratio of 7.85. The company experienced significant dilution, with a share count change of 3760.8% over 5 years reported in FY2025. Free cash flow was -$22.9M in FY2022, identical to operating cash flow of -$22.9M.
Valuation and performance
ProMIS Neurosciences carries a market cap of $73.1M and an enterprise value of $65.5M. The stock trades at a price-to-book ratio of 2.4x. Because earnings and sales are minimal, traditional multiples compare against US-listed Healthcare peers where the median trailing P/E is 24.6x, forward P/E is 17.3x, and price-to-sales is 4.1x. Over the past year, PMN shares declined 30.6%, underperforming the S&P 500 (SPY) return of 16.8%, while its 5-year return of -96.4% trails the benchmark's 83.0% gain.
What analysts expect
Wall Street coverage includes 6 Strong Buy ratings, 2 Buy ratings, and 0 Hold or Sell ratings. The mean price target is $42.95, representing a target vs last close of 427.0% compared to the October 16, 2026 share price of $8.15. For the current fiscal year ending December 31, 2026, consensus projects an EPS estimate of -$7.36 and revenue of $0. For the next fiscal year, 8 analysts project revenue of $0 and EPS of -$5.48. The next earnings date is November 11, 2026.
Key risks and what to watch
- The business model relies on development milestones with consensus revenue estimates of $0 for both FY2026 and FY2027.
- Operating cash burn remains significant, evidenced by an annual free cash flow of -$22.9M in FY2022.
- Historical equity dilution has been high, with the 5-year share count change reaching 3760.8%.
- The stock trades 36.6% below its 200-day average following extended volatility.
AI-generated research summary. Written with AI from Quotelinks data as of October 16, 2026 and checked so every figure matches that data. For information only, not investment advice. Disclaimer
About this PMN AI stock analysis
This page is an AI-written research summary of ProMIS Neurosciences, Inc. (PMN). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.
Related: PMN income statement, PMN balance sheet, PMN key metrics, PMN analyst forecast, PMN chart. See the PMN stock overview for the latest quote and news.
PMN AI stock analysis FAQ
Does ProMIS Neurosciences pay a dividend?
No, ProMIS Neurosciences does not pay a dividend.
What is the mean analyst price target for PMN?
The mean price target from analysts is $42.95, which sits 427.0% above the last close of $8.15 on October 16, 2026.
How much cash does ProMIS Neurosciences hold?
As of June 30, 2026, the company held $53.5M in cash and short-term investments, supporting a current ratio of 7.85.
What are Wall Street's expectations for upcoming revenue and earnings?
For the fiscal year ending December 31, 2026, analysts estimate an EPS of -$7.36 on revenue of $0, with the next earnings release scheduled for November 11, 2026.